6533b825fe1ef96bd1281ab6
RESEARCH PRODUCT
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Karoline B KuchenbaeckerSusan L NeuhausenMark RobsonDaniel BarrowdaleLesley McguffogAnna Marie MulliganIrene L AndrulisAmanda B SpurdleMarjanka K SchmidtRita K SchmutzlerChristoph EngelBarbara WappenschmidtHeli NevanlinnaMads ThomassenMelissa SoutheyPaolo RadiceSusan J RamusSusan M DomchekKatherine L NathansonAndrew LeeSue HealeyRobert L NussbaumTimothy R RebbeckBanu K ArunPaul JamesBeth Y KarlanJenny LesterIlana CassThe Breast Cancer Family RegistryMary Beth TerryMary B DalyDavid E GoldgarSaundra S BuysRamunas JanaviciusLaima TihomirovaNadine TungCecilia M DorflingElizabeth J Van RensburgLinda SteeleThomas V O HansenBent EjlertsenAnne-marie GerdesFinn C NielsenJoe DennisJulie CunninghamSteven HartSusan SlagerAna OsorioJavier BenitezMercedes DuranJeffrey N WeitzelIsaac TafurMary HanderPaolo PeterlongoSiranoush ManoukianBernard PeisselGaia RoversiGiulietta ScuveraBernardo BonanniPaolo MarianiSara VolorioRiccardo DolcettiLiliana VarescoLaura PapiMaria Grazia TibilettiGiuseppe GianniniFlorentia FostiraIrene KonstantopoulouJudy GarberUte HamannAlan DonaldsonCarole BrewerClaire FooD Gareth EvansDebra FrostDiana EcclesThe Embrace StudyFiona DouglasAngela BradyJackie CookMarc TischkowitzJulian AdlardJulian BarwellKai-ren OngLisa WalkerLouise IzattLucy E SideM John KennedyMark T RogersMary E PorteousPatrick J MorrisonRadka PlatteRos EelesRosemarie DavidsonShirley HodgsonSteve EllisAndrew K GodwinKerstin RhiemAlfons MeindlNina DitschNorbert ArnoldHansjoerg PlendlDieter NiederacherChristian SutterDoris SteinemannNadja Bogdanova-markovKarin KastRaymonda Varon-mateevaShan Wang-gohrkeAndrea GehrigBirgid MarkiefkaBruno BuecherCédrick LefolDominique Stoppa-lyonnetEtienne RouleauFabienne PrieurFrancesca DamiolaThe Gemo Study CollaboratorsLaure BarjhouxLaurence FaivreMichel LongyNicolas SevenetOlga M SinilnikovaSylvie MazoyerValérie BonadonaVirginie Caux-moncoutierClaudine IsaacsTom Van MaerkenKathleen ClaesMarion PiedmonteLesley AndrewsJohn HaysGustavo C RodriguezTrinidad CaldesMiguel De La HoyaSofia KhanFrans Bl HogervorstCora M AalfsJl De LangeHanne Ej Meijers-heijboerAnnemarie H Van Der HoutJuul T WijnenKep Van RoozendaalArjen R MensenkampAns Mw Van Den OuwelandCarolien Hm Van DeurzenRob B Van Der Luijt. HebonEdith OlahOrland DiezConxi LazaroIgnacio BlancoAlex TeuléMireia MenendezAnna JakubowskaJan LubinskiCezary CybulskiJacek GronwaldKatarzyna Jaworska-bieniekKatarzyna DurdaAdalgeir ArasonChristine MaugardPenny SoucyMarco MontagnaSimona AgataManuel R TeixeiraThe Kconfab InvestigatorsCurtis OlswoldNoralane LindorVernon S PankratzEmily HallbergXianshu WangCsilla I SzaboJoseph VijaiLauren JacobsMarina CorinesAnne LincolnAndreas BergerAnneliese Fink-retterChristian F SingerChristine RappaportDaphne Gschwantler KaulichGeorg PfeilerMuy-kheng TeaCatherine M PhelanPhuong L MaiMark H GreeneGad RennertEvgeny N ImyanitovGord GlendonAmanda Ewart TolandAnders BojesenInge Sokilde PedersenUffe Birk JensenMaria A CaligoEitan FriedmanRaanan BergerYael LaitmanJohanna RantalaBrita ArverNiklas LomanAke BorgHans EhrencronaOlufunmilayo I OlopadeJacques SimardDouglas F EastonGeorgia Chenevix-trenchKenneth OffitFergus J CouchAntonis C AntoniouOn Behalf Of Cimbasubject
Cancer ResearchReceptor ErbB-2Genes BRCA2BRCALOCIGenes BRCA1MODIFIERSVARIANTSErbB-2610 Medical sciences MedicineDuctalReceptorsMedicine and Health SciencesINVESTIGATORSBreastskin and connective tissue diseasesProgesteroneMedicine(all)Carcinoma Ductal BreastMiddle AgedAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2; Cancer Research; OncologyOncologyReceptors EstrogenTUMOR SUBTYPESFemaleReceptors ProgesteroneReceptorResearch ArticleAdultHeterozygote610Breast NeoplasmsMEDULLARY CARCINOMAOVARIAN-CANCERLobularHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONAllelesAgedNeoplasm StagingAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2CONSORTIUMCarcinomaBRCA1EstrogenBRCA2Carcinoma LobularESTROGEN-RECEPTORGenesNeoplasm Gradingdescription
Introduction More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers. Methods We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- (TN) status; morphologic subtypes; histological grade; and nodal involvement. Results The estimated BC hazard ratios (HRs) for the 74 known BC alleles in BRCA1 carriers exhibited moderate correlations with the corresponding odds ratios from the general population. However, their associations with ER-positive BC in BRCA1 carriers were more consistent with the ER-positive associations in the general population (intraclass correlation (ICC) = 0.61, 95% confidence interval (CI): 0.45 to 0.74), and the same was true when considering ER-negative associations in both groups (ICC = 0.59, 95% CI: 0.42 to 0.72). Similarly, there was strong correlation between the ER-positive associations for BRCA1 and BRCA2 carriers (ICC = 0.67, 95% CI: 0.52 to 0.78), whereas ER-positive associations in any one of the groups were generally inconsistent with ER-negative associations in any of the others. After stratifying by ER status in mutation carriers, additional significant associations were observed. Several previously unreported variants exhibited associations at P <10−6 in the analyses by PR status, HER2 status, TN phenotype, morphologic subtypes, histological grade and nodal involvement. Conclusions Differences in associations of common BC susceptibility alleles between BRCA1 and BRCA2 carriers and the general population are explained to a large extent by differences in the prevalence of ER-positive and ER-negative tumors. Estimates of the risks associated with these variants based on population-based studies are likely to be applicable to mutation carriers after taking ER status into account, which has implications for risk prediction. Electronic supplementary material The online version of this article (doi:10.1186/s13058-014-0492-9) contains supplementary material, which is available to authorized users.
year | journal | country | edition | language |
---|---|---|---|---|
2014-12-31 | Breast Cancer Research |